The administration of a high dose of intravenous FGF21 reverses hepatic steatosis, improves insulin sensitivity, and decreases serum glucose levels in mice with NAFLD (Xu et al., 2009). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.